MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) announced today a synopsis of clinical data on the Endeavor™ Drug Eluting Coronary Stent to be presented to an FDA Advisory Panel on October 10. This announcement was made in conjunction with the release of FDA Advisory Panel materials by the U.S. Food and Drug Administration and includes a pooled data analysis of the major trials encompassing the ENDEAVOR clinical program as well as newly released nine-month results from the ENDEAVOR IV clinical trial. The Advisory Panel will consider whether to recommend approval of the device to the FDA. The Panel’s recommendation will be subject to FDA approval.
